BAY2927088

DRUG5 trials

Sponsors

Bayer

Conditions

Advanced Non-small Cell Lung CancerAdvanced Solid TumorsEGFR MutationHER2 MutationHealthy Volunteers

Phase 1

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

CompletedNCT06329895

BayerAdvanced Non-small Cell Lung Cancer, EGFR Mutation, Healthy Volunteers +1

Start: 2024-03-25End: 2024-06-10Updated: 2024-07-05

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

CompletedNCT06348888

BayerAdvanced Non-small Cell Lung Cancer, EGFR Mutation, Healthy Volunteers +1

Start: 2024-04-10End: 2024-06-12Updated: 2024-06-20

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

CompletedNCT06360211

BayerAdvanced Non-small Cell Lung Cancer, EGFR Mutation, Healthy Volunteers +1

Start: 2024-04-17End: 2024-06-28Updated: 2024-07-03

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

CompletedNCT06378658

BayerAdvanced Non-small Cell Lung Cancer, EGFR Mutation, Healthy Volunteers +1

Start: 2024-03-29End: 2024-06-11Updated: 2024-07-05

Phase 2

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

RecruitingNCT06760819

BayerAdvanced Solid Tumors, HER2 Mutation

Start: 2025-02-13End: 2029-10-26Target: 111Updated: 2026-09-03

Related Papers

panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with <i>HER2</i> -activating mutations.

Journal of Clinical Oncology2025-05-28